Through the transaction, Lantheus has acquired OCTEVY™, a registrational-stage PET diagnostic imaging agent targeting neuroendocrine tumors, which complements Lantheus’ therapeutic candidate PNT2003, ...

TechneLite. Rounding out Lantheus’ meaningful contributors to its top line is TechneLite, a generator of technetium, a ...

Analysts raise price forecasts. Lantheus To Buy Evergreen Theragnostics For Over $1 Billion To Bolster Its Cancer Radiopharmaceutical Portfolio Lantheus strengthens its radiopharmaceutical ...

The acquisition also advances Lantheus’ capabilities with the addition of Evergreen’s radioligand therapy manufacturing infrastructure, including a revenue-generating CDMO business.

Lantheus (LNTH) Holdings announced that it has completed its previously announced acquisition of Evergreen Theragnostics, a clinical-stage radiopharmaceutical company. The acquisition was first ...